提醒成功
微信/QQ登錄
搜索
首頁
| 產品規范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00053 |
| Application | Flow cytometry, animal model study |
| Aliases | VEGF, VEGF-A, vascular endothelial growth factor A |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human VEGF-A |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. |
Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody B00053
聯系方式
CONTACT-
聯系電話:
0731-88388785 -
公司郵箱:
sales@promab.cn -
公司地址:
湖南省長沙市高新開發區林語路239號順暢產業園5樓
官方微信
產品中心
Product技術服務
service客戶留言
message